GRI Bio (GRI) Competitors $0.42 -0.02 (-4.64%) As of 02/21/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GRI vs. LPCN, APRE, LPTX, MIRA, OKUR, COCP, NNVC, GLYC, MRKR, and ATHAShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Lipocine (LPCN), Aprea Therapeutics (APRE), Leap Therapeutics (LPTX), MIRA Pharmaceuticals (MIRA), OnKure Therapeutics (OKUR), Cocrystal Pharma (COCP), NanoViricides (NNVC), GlycoMimetics (GLYC), Marker Therapeutics (MRKR), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Lipocine Aprea Therapeutics Leap Therapeutics MIRA Pharmaceuticals OnKure Therapeutics Cocrystal Pharma NanoViricides GlycoMimetics Marker Therapeutics Athira Pharma Lipocine (NASDAQ:LPCN) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Does the media prefer LPCN or GRI? In the previous week, GRI Bio had 5 more articles in the media than Lipocine. MarketBeat recorded 6 mentions for GRI Bio and 1 mentions for Lipocine. Lipocine's average media sentiment score of 0.00 beat GRI Bio's score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, LPCN or GRI? Lipocine has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -2.15, suggesting that its share price is 315% less volatile than the S&P 500. Is LPCN or GRI more profitable? Lipocine's return on equity of -19.17% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -19.17% -17.60% GRI Bio N/A -289.05%-165.01% Do analysts recommend LPCN or GRI? Lipocine presently has a consensus price target of $10.00, indicating a potential upside of 195.86%. GRI Bio has a consensus price target of $195.50, indicating a potential upside of 47,008.43%. Given GRI Bio's higher possible upside, analysts clearly believe GRI Bio is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in LPCN or GRI? 9.1% of Lipocine shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 6.1% of Lipocine shares are owned by company insiders. Comparatively, 0.1% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, LPCN or GRI? GRI Bio has lower revenue, but higher earnings than Lipocine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$500K36.17-$16.35M-$0.76-4.45GRI BioN/AN/A-$13.04MN/AN/A Does the MarketBeat Community believe in LPCN or GRI? Lipocine received 344 more outperform votes than GRI Bio when rated by MarketBeat users. However, 100.00% of users gave GRI Bio an outperform vote while only 68.17% of users gave Lipocine an outperform vote. CompanyUnderperformOutperformLipocineOutperform Votes34768.17% Underperform Votes16231.83% GRI BioOutperform Votes3100.00% Underperform VotesNo Votes SummaryLipocine beats GRI Bio on 7 of the 13 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.89M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.7326.0419.11Price / SalesN/A306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book0.086.717.644.62Net Income-$13.04M$138.33M$3.18B$245.85M7 Day Performance-95.56%-2.63%-2.00%-2.61%1 Month Performance-96.37%-2.33%-0.44%-2.14%1 Year Performance-99.78%-5.33%16.44%12.98% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.3738 of 5 stars$0.42-4.6%$195.50+47,008.4%-96.7%$3.89MN/A0.001Stock SplitNews CoverageLPCNLipocine1.6881 of 5 stars$3.63+2.5%$10.00+175.5%-14.4%$19.42M$500,000.00-4.7810Analyst ForecastGap DownAPREAprea Therapeutics2.1246 of 5 stars$3.58+1.3%$15.50+333.6%-58.3%$19.41M$580,000.00-1.277LPTXLeap Therapeutics1.3579 of 5 stars$0.50-0.8%$4.92+876.1%-84.0%$19.30MN/A-0.2640MIRAMIRA Pharmaceuticals2.1109 of 5 stars$1.16-2.5%$14.00+1,106.9%+1.9%$19.21MN/A-2.072OKUROnKure Therapeutics2.6327 of 5 stars$5.74+2.0%$36.00+527.2%N/A$19.17MN/A-0.47N/ACOCPCocrystal Pharma2.6063 of 5 stars$1.87+0.5%$7.00+274.3%+32.7%$19.02MN/A-1.0110NNVCNanoViricidesN/A$1.35+4.7%N/A+21.0%$18.83MN/A-1.7820Gap UpGLYCGlycoMimetics4.1636 of 5 stars$0.29+2.2%$8.00+2,658.6%-90.1%$18.70M$10,000.000.0050Analyst ForecastNews CoverageGap DownHigh Trading VolumeMRKRMarker Therapeutics4.3474 of 5 stars$1.72+1.2%$19.00+1,004.7%-59.9%$18.42M$3.31M0.0060ATHAAthira Pharma2.9125 of 5 stars$0.47+6.4%$13.83+2,855.8%-88.3%$18.10MN/A-0.1640 Related Companies and Tools Related Companies LPCN Alternatives APRE Alternatives LPTX Alternatives MIRA Alternatives OKUR Alternatives COCP Alternatives NNVC Alternatives GLYC Alternatives MRKR Alternatives ATHA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
